JIMD reportsPub Date : 2026-11-13eCollection Date: 2026-11-01DOI: 10.1002/jmd2.70138
Hang Su, Duoling Li, Meng Yu, Junhong Guo, Xuefan Yu, Xiaojing Wei, Xueqin Song, Zhe Zhao, Mingming Ma, Kai Ma, Ting Chang, Xiangqi Cao, Xia Li, Juan Kang, Zaiqiang Zhang, Hong Han, Zhuyan Wang, Li Di, Ting Xiong, Sha Sun, Jun Wu, Shu Zhang, Cuiping Zhao, Yuan Sun, Weili Zhao, Zhiyun Wang, Yali Zhang, Haiping Wang, Ying Li, Chuanzhu Yan, Zhaoxia Wang, Yuying Zhao
{"title":"High-Risk Screening for Late-Onset Pompe Disease in Northern China: Prevalence, Genotypic Spectrum, and Diagnostic Challenges.","authors":"Hang Su, Duoling Li, Meng Yu, Junhong Guo, Xuefan Yu, Xiaojing Wei, Xueqin Song, Zhe Zhao, Mingming Ma, Kai Ma, Ting Chang, Xiangqi Cao, Xia Li, Juan Kang, Zaiqiang Zhang, Hong Han, Zhuyan Wang, Li Di, Ting Xiong, Sha Sun, Jun Wu, Shu Zhang, Cuiping Zhao, Yuan Sun, Weili Zhao, Zhiyun Wang, Yali Zhang, Haiping Wang, Ying Li, Chuanzhu Yan, Zhaoxia Wang, Yuying Zhao","doi":"10.1002/jmd2.70138","DOIUrl":"10.1002/jmd2.70138","url":null,"abstract":"<p><p>Late-onset Pompe disease (LOPD), also known as late-onset glycogen storage disease Type II, is caused by a genetic deficiency of the lysosomal enzyme acid α-glucosidase (GAA). LOPD typically results in progressive weakness of the limb-girdle and respiratory muscles and is often accompanied by the involvement of other systems, such as skeleton, smooth muscle, and the cerebrovascular system. The incidence of LOPD in China remains unknown, underscoring the need for large-scale epidemiological studies to better characterize the clinical spectrum. This prospective, multicenter, observational cohort study was conducted across 39 neurology centers in 12 northern Chinese provinces. A novel pragmatic approach was utilized, which included the development and application of a standardized high-risk profile for LOPD suspicion, derived from collective diagnostic and therapeutic experience throughout the region. Individuals meeting 2 or more criteria in this predefined high-risk profile were enrolled. Subsequent screening involved initial analysis of GAA enzyme activity using dried blood spot (DBS) testing and patients with deficient enzyme activity underwent confirmatory genetic testing to establish a definitive LOPD diagnosis. Between January 2022 and December 2024, 1878 high-risk patients were enrolled. Screening identified 46 patients (2.45%) diagnosed with LOPD based on DBS analysis and subsequent genetic confirmation. This study demonstrates a significant prevalence of LOPD among a clinically high-risk population in Northern China. These findings underscore the critical importance of targeted screening programs for early identification. Early diagnosis enables timely initiation of enzyme replacement therapy (ERT), which can significantly mitigate the disease course, improve quality of life, and reduce long-term healthcare burden.</p>","PeriodicalId":14930,"journal":{"name":"JIMD reports","volume":"67 6","pages":"e70138"},"PeriodicalIF":1.8,"publicationDate":"2026-11-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13768598/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149406330","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
JIMD reportsPub Date : 2026-11-13eCollection Date: 2026-11-01DOI: 10.1002/jmd2.70135
Maria C Laso-Salazar, Debra S Regier, Kimberly A Chapman, Samantha Vergano, Nadia Falah, Jennifer L Harmon, Nina Mickle, Natasha E Shur, Christina L Grant, Erin MacLeod, Danielle Starin, Jamie L Fraser, Eyby Leon
{"title":"Death Secondary to Brain Herniation in Classic MSUD Patients: A Case Series From One Center.","authors":"Maria C Laso-Salazar, Debra S Regier, Kimberly A Chapman, Samantha Vergano, Nadia Falah, Jennifer L Harmon, Nina Mickle, Natasha E Shur, Christina L Grant, Erin MacLeod, Danielle Starin, Jamie L Fraser, Eyby Leon","doi":"10.1002/jmd2.70135","DOIUrl":"https://doi.org/10.1002/jmd2.70135","url":null,"abstract":"<p><p>Maple Syrup Urine Disease (MSUD) is an inborn error of metabolism associated with defects in the branched-chain alpha-keto acid dehydrogenase complex. Despite careful management, patients may experience metabolic decompensation, elevation of leucine levels, cerebral edema, brain herniation, and death. Two populations have been reported to be the most affected: Mennonite and Ashkenazi Jewish. There are three genes associated with this condition, with <i>DBT</i> being the least frequently involved and usually associated with milder or thiamine-responsive MSUD. We present four patients, three of Salvadoran and one of Afghan ancestry, diagnosed with classic MSUD who developed cerebral edema, herniated, and died despite aggressive medical management. All patients had pathogenic variants in the <i>DBT</i> gene and were not thiamine-responsive. They all presented with elevated plasma leucine levels that were not their highest recorded after diagnosis. Decompensation in an MSUD patient should be approached with extreme caution, considering that brain edema can progress very rapidly to brain herniation and death, especially since there are no reliable biochemical markers that can predict this fatal outcome. The phenotype and genotype of classic MSUD need to be described more thoroughly, since they can have a more severe presentation and higher mortality rate than previously reported and might be misleading to the treating clinician when genetic testing results are of uncertain significance. Our cohort presents four patients of non-Mennonite or Ashkenazi Jewish descent with fatal brain herniation occurring rapidly without being preceded by their highest plasma leucine peak registered, significant ketonuria, elevated anion gap, and/or hyponatremia on admission. This highlights the importance of studying different populations affected by MSUD and considering liver transplantation as the potential best treatment option for certain patients.</p>","PeriodicalId":14930,"journal":{"name":"JIMD reports","volume":"67 6","pages":"e70135"},"PeriodicalIF":1.8,"publicationDate":"2026-11-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13760599/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149406299","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
JIMD reportsPub Date : 2026-11-09eCollection Date: 2026-11-01DOI: 10.1002/jmd2.70122
Simona D'Amore, Ma Cabides, Uma Ramaswami
{"title":"Raised Amylase as a Potential Marker of Vascular Dysfunction and Inflammation in Fabry Disease.","authors":"Simona D'Amore, Ma Cabides, Uma Ramaswami","doi":"10.1002/jmd2.70122","DOIUrl":"10.1002/jmd2.70122","url":null,"abstract":"<p><p>Fabry disease (FD) is a X-linked disorder caused by deficiency of alpha-galactosidase A (AGAL), leading to progressive accumulation of globotriaosylceramide (Gb3) and globotriaosylsphingosine (lyso-Gb3). While renal, cardiac and cerebrovascular complications are well described, pancreatic involvement remains poorly characterised. We retrospectively evaluated the clinical and biochemical features of FD patients with elevated serum amylase levels and explored associations with disease severity, treatment status, inflammation and vascular dysfunction. Sixty-two patients (35 males, 27 females; median age 53.9 years [IQR 42.1-64.5]) showed hyperamylasaemia (> 100 U/L). None had known pancreatic disease or significant alcohol intake. Median amylase levels were 114.5 U/L (IQR 104-137). Seven patients were obese (body mass index ≥ 30 kg/m<sup>2</sup>). No significant differences in amylase levels were observed according to sex, genotype, treatment status or renal/cerebrovascular involvement. However, patients with cardiac involvement had higher amylase levels than those without cardiac manifestations (median 128 [IQR 104-149] vs. 113 U/L [IQR 104.3-125]; <i>p</i> = 0.039). Amylase levels were not associated with AGAL activity, lyso-Gb3 concentrations, renal function, liver function, d-dimer, lactate dehydrogenase or lipid profile. Significant correlations were observed with age (<i>r</i> = 0.292; <i>p</i> = 0.021), body mass index (<i>r</i> = -0.382; <i>p</i> = 0.003) and lipoprotein(a) levels (<i>r</i> = 0.413; <i>p</i> = 0.004). Notably, elevated amylase occurred in the absence of clinically evident pancreatic disease, significant alcohol consumption or liver dysfunction. These findings suggest that hyperamylasaemia may represent an underrecognised biochemical feature of FD, potentially reflecting vascular and inflammatory mechanisms rather than overt pancreatic disease. Further studies are needed to clarify the pathophysiological significance of hyperamylasaemia in FD.</p>","PeriodicalId":14930,"journal":{"name":"JIMD reports","volume":"67 6","pages":"e70122"},"PeriodicalIF":1.8,"publicationDate":"2026-11-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13746100/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149379030","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
JIMD reportsPub Date : 2026-11-05DOI: 10.1002/jmd2.70136
Samuel D. Moran, Erika F. Augustine, Jonathan W. Mink, Marianna Pereira-Freitas, Naomi S. Taggart, Jennifer Vermilion, Amy E. Vierhile, Heather R. Adams
{"title":"Cognitive Test Performance in CLN3 Disease Is Associated With the CLN3 Staging System (CLN3SS)","authors":"Samuel D. Moran, Erika F. Augustine, Jonathan W. Mink, Marianna Pereira-Freitas, Naomi S. Taggart, Jennifer Vermilion, Amy E. Vierhile, Heather R. Adams","doi":"10.1002/jmd2.70136","DOIUrl":"https://doi.org/10.1002/jmd2.70136","url":null,"abstract":"<p>CLN3 disease is an inherited neurodegenerative disease, typically with childhood onset, and characterized by vision loss, seizures, cognitive decline, and difficulties. The CLN3 Staging System (CLN3SS) characterizes disease progression. Our aim was to assess differences in cognitive test scores in relation to CLN3SS among individuals with CLN3 disease. We evaluated the relationship between cognitive test performance and the CLN3SS in individuals with genetically confirmed CLN3 disease. Participants completed tasks of verbal reasoning, vocabulary knowledge, attention, fund of information, and ability to recite the alphabet. One-way ANOVA testing assessed differences in mean cognitive test score among CLN3SS score groups, and chi-square testing was used to compare the proportion in each CLN3SS group that could recite the alphabet. Data were evaluated from a sample of 85 individuals with a total 245 CLN3SS assessments conducted within 6 months of their cognitive testing, A significant decrease in test scores was found between CLN3SS Stages 1 (vision loss present) and 2 (vision loss and seizures present) for each of the cognitive tests. The proportion of participants able to recite the alphabet also decreased from Stage 1 to Stage 2 (<i>χ</i><sup>2</sup> = 12.1, <i>p</i> < 0.01). Cognitive ability declines with advanced disease severity in CLN3 disease, though motor disability in Stage 3 likely contributes to difficulty participating in cognitive assessment at this later disease stage. Understanding the relationship between cognition and CLN3 disease stage may help guide decision making, that is, determining who could or should undergo cognitive assessment for clinical care or for group stratification in disease modifying clinical trials.</p>","PeriodicalId":14930,"journal":{"name":"JIMD reports","volume":"67 6","pages":""},"PeriodicalIF":1.8,"publicationDate":"2026-11-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/jmd2.70136","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149356098","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
JIMD reportsPub Date : 2026-11-05DOI: 10.1002/jmd2.70134
M. Schadeck, A. Tankeu, J. Elmers, E. Hewer, F. Maurer, P. Monney, M. Théaudin, C. Tran
{"title":"Genotype and Phenotype Description in Individuals With GYG1 Variants—A Case Report and Systematic Review","authors":"M. Schadeck, A. Tankeu, J. Elmers, E. Hewer, F. Maurer, P. Monney, M. Théaudin, C. Tran","doi":"10.1002/jmd2.70134","DOIUrl":"10.1002/jmd2.70134","url":null,"abstract":"<p>Glycogen Storage Disease Type XV (GSD XV) is a rare autosomal recessive disorder caused by biallelic pathogenic variants in <i>GYG1</i>, encoding glycogenin-1. Although primarily a myopathic disease, cardiac involvement is increasingly recognized and overlapping features with other neuromuscular disorders contribute to underdiagnosis. We performed a systematic search of databases without restrictions on publication dates. Twenty-one articles describing individuals with GSD XV were included, providing clinical, histological, and genetic data. In addition to the systematic review, we present an illustrative case of GSD XV diagnosed at our institution. We identified 49 individuals, of whom 98% were symptomatic with onset ranging from childhood to late adulthood; manifestations were isolated neuromuscular (81.6%), cardiac (8.2%), or mixed (8.2%). One case (2.0%) was asymptomatic. Among neuromuscular cases, 12% required a walking aid, while four cardiac patients required implantable cardioverter-defibrillators and two underwent heart transplantation. Muscle biopsy frequently revealed PAS-positive, diastase-resistant polyglucosan bodies, although polyglucosan bodies were not consistently identified by electron microscopy. Molecular diagnosis was confirmed in all cases, with c.143+3G>C in <i>GYG1</i> being the most prevalent variant, homozygous in 36.7% of patients and associated with both juvenile and adult-onset phenotypes. GSD XV should be considered in cases with unexplained myopathy or cardiomyopathy, regardless of age at onset. Genetic testing remains the gold standard for diagnosis, although muscle biopsy can guide investigations, particularly in atypical cases or when genetic analysis is inconclusive. Further studies are needed to clarify the full clinical spectrum, refine genotype–phenotype correlations, and guide long-term management strategies.</p>","PeriodicalId":14930,"journal":{"name":"JIMD reports","volume":"67 6","pages":""},"PeriodicalIF":1.8,"publicationDate":"2026-11-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13737462/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149342291","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
JIMD reportsPub Date : 2026-10-30DOI: 10.1002/jmd2.70127
Eugen Mengel, Sinziana Stanescu, Alessio Di Fonzo, Aimee Donald, Tanya Collin-Histed, Laurence Djatche, Idaira Rodriguez Santana, Jagan Mohan Palli, Maria Gabriela Perichon, Ruth Pulikottil-Jacob, Fatih S. Ezgu
{"title":"Clinical History and Burden of Gaucher Disease Type 3: A Cross-Sectional Multinational Study","authors":"Eugen Mengel, Sinziana Stanescu, Alessio Di Fonzo, Aimee Donald, Tanya Collin-Histed, Laurence Djatche, Idaira Rodriguez Santana, Jagan Mohan Palli, Maria Gabriela Perichon, Ruth Pulikottil-Jacob, Fatih S. Ezgu","doi":"10.1002/jmd2.70127","DOIUrl":"10.1002/jmd2.70127","url":null,"abstract":"<p>Gaucher disease Type 3 (GD3) is a rare genetic neurodegenerative disorder, characterized by heterogeneity in symptom burden, disease severity, and progression. There is limited evidence on the burden of GD3. This retrospective, cross-sectional study estimated the burden of illness associated with GD3 using descriptive analyses of clinician- and patient/caregiver-reported data from Germany, Italy, Spain, Turkey, the UK, and the US. A total of 79 patients were enrolled in the study; 39 patients and 38 caregivers completed the patient/caregiver survey. The majority of patients were male (74.7%) and under 18 years old (55.7%), with an average age at index (study enrolment date) of 17.0 years (SD = 9.0). Patients received a GD3 diagnosis at a mean age of 8.2 years (SD = 6.4). The most common first non-neurological symptoms experienced were splenomegaly (49.4%), anemia (44.3%), and enlarged abdomen (43.0%), while the first most common neurological manifestations reported included eye movement disorders (54.4%), epilepsy (35.4%), and neurodevelopmental delay (34.2%). Approximately half of patients experienced falls (55.7%) or difficulty with personal care (53.2%). Nearly half of patients (45.6%) had at least one hospitalization, with a mean (SD) of 2.1 (1.7) hospitalizations per patient, in the 2 years pre-index. Caregivers were predominantly female (86.8%) and provided an average of 63.3 h of care per week (SD = 40.2). They reported high work impairment (70.3%, SD = 22.0; WPAI) and reduced quality of life (CarerQoL-7D mean = 67.0, SD = 15.8). This study characterizes the real-world burden of GD3, providing an up-to-date, multinational perspective on its clinical history and impact on patients, caregivers, healthcare systems, and society.</p>","PeriodicalId":14930,"journal":{"name":"JIMD reports","volume":"67 6","pages":""},"PeriodicalIF":1.8,"publicationDate":"2026-10-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13722778/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149321444","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
JIMD reportsPub Date : 2026-10-22DOI: 10.1002/jmd2.70128
Margaretha G. M. Roemer, Monique Chevallier, Marie van Dijk, André B. P. van Kuilenburg, Kasper W. ter Horst, Janneke C. Zant
{"title":"Alder–Reilly Anomaly Leading to Incidental Diagnosis of MPS VII in an Asymptomatic Adult","authors":"Margaretha G. M. Roemer, Monique Chevallier, Marie van Dijk, André B. P. van Kuilenburg, Kasper W. ter Horst, Janneke C. Zant","doi":"10.1002/jmd2.70128","DOIUrl":"10.1002/jmd2.70128","url":null,"abstract":"<p>Mucopolysaccharidosis type VII (MPS VII; Sly syndrome) is a rare autosomal recessive lysosomal storage disorder caused by deficiency of β-glucuronidase due to pathogenic variants in the <i>GUSB</i> gene. Impaired degradation of glycosaminoglycans (GAGs) results in multiorgan dysfunction with highly variable clinical presentation, ranging from severe neonatal disease to attenuated adult phenotypes. We report an incidental diagnosis of MPS VII in a 31-year-old woman identified through routine laboratory testing. Review of a peripheral blood smear was prompted by automated hematology analyzer flags and revealed Alder–Reilly anomaly with characteristic aberrant leukocyte granulation. Subsequent biochemical analysis showed elevated urinary dermatan sulfate and heparan sulfate, alongside reduced β-glucuronidase activity (~2%–3% of normal). Genetic testing of <i>GUSB</i> identified compound heterozygosity for a likely pathogenic frameshift variant (c.133_134del) and a missense variant (c.454G>A) previously associated with pseudodeficiency. Despite biochemical and genetic findings consistent with MPS VII, the patient exhibited no typical clinical manifestations, and detailed phenotyping showed no organ involvement. This case illustrates an atypical, asymptomatic presentation of MPS VII diagnosed in adulthood, in which Alder–Reilly anomaly served as a critical diagnostic clue. The combination of a null allele with a pseudodeficiency-associated variant resulted in reduced enzyme activity without overt disease. These findings highlight the importance of peripheral blood smear evaluation in identifying lysosomal storage disorders and underscore the complexity of genotype–phenotype correlations in MPS VII.</p>","PeriodicalId":14930,"journal":{"name":"JIMD reports","volume":"67 6","pages":""},"PeriodicalIF":1.8,"publicationDate":"2026-10-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13691299/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149244609","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
JIMD reportsPub Date : 2026-10-14DOI: 10.1002/jmd2.70132
Elena Martín-Hernández, Delia Barrio-Carreras, María Martín-Cazaña, Luis Miguel García-Cárdaba, Carmen Martín-Fernández, Patricia Pérez-Mohand, Teresa Hernández Chamorro, Berta Zamora Crespo, Pedro Ruiz-Sala, Patricia Alcaide Alonso, Pilar Quijada-Fraile
{"title":"Fatty Acid Oxidation Disorders Detected by Newborn Screening: Clinical, Biochemical and Genetic Spectrum in a Single-Center Cohort","authors":"Elena Martín-Hernández, Delia Barrio-Carreras, María Martín-Cazaña, Luis Miguel García-Cárdaba, Carmen Martín-Fernández, Patricia Pérez-Mohand, Teresa Hernández Chamorro, Berta Zamora Crespo, Pedro Ruiz-Sala, Patricia Alcaide Alonso, Pilar Quijada-Fraile","doi":"10.1002/jmd2.70132","DOIUrl":"10.1002/jmd2.70132","url":null,"abstract":"<p>Newborn screening (NBS) has significantly improved early detection and survival in fatty acid oxidation disorders (FAODs). However, the expanding phenotypic spectrum challenges prognostic stratification, and long-term morbidity remains incompletely characterized. We conducted an observational, retrospective, single-center study of patients with FAODs identified through NBS and followed between 2011 and 2024. Clinical, biochemical, genetic, and nutritional data were extracted from medical records. Correlations between biochemical markers, enzymatic activity, and clinical outcomes were analyzed. The study was approved by the Research Committee of the Instituto de Investigación, Hospital 12 de Octubre (Madrid). Sixty-five patients were included: 42 MCADD, 11 VLCADD, 5 LCHADD, 2 CPT1D, 3 CPT2D, 1 CACTD, and 1 MADD. Median age at last follow-up was 7.2 years (range 0.4–13.6). Two patients died during follow-up (overall mortality 3.1%). In MCADD, confirmatory C8 concentrations correlated with residual enzyme activity and metabolic decompensations. In VLCADD, NBS and confirmatory C14:1 levels correlated with enzyme activity but not with clinical severity. VLCADD showed marked clinical heterogeneity, whereas LCHADD patients had the highest disease burden and required the most intensive nutritional management. Overall, 40% of patients experienced at least one metabolic decompensation, occurring significantly more frequently in LC-FAOD than in MCADD. Neuropsychological manifestations were observed in 16.9% of patients. In summary, NBS markedly improves survival in FAODs, but morbidity remains substantial, particularly in LC-FAOD. Current biochemical markers are useful for early risk stratification but remain insufficient to predict long-term clinical severity. These findings support individualized multidisciplinary follow-up, including specialized nutritional care and systematic neuropsychological assessment.</p>","PeriodicalId":14930,"journal":{"name":"JIMD reports","volume":"67 6","pages":""},"PeriodicalIF":1.8,"publicationDate":"2026-10-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13662738/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149193833","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
JIMD reportsPub Date : 2026-10-08DOI: 10.1002/jmd2.70121
Tirza Boschma, Désirée Y. van Haaften-Visser, Maaike C. de Vries, Roos Dijkstra, Amaya Zinck, Esmeralda Oussoren, Terry G. J. Derks, Andrea B. Haijer-Schreuder
{"title":"Impacting Rare Diseases Healthcare by Case-Based Telelearning: Description of the Dutch Pilot Metabolic Diseases ECHO","authors":"Tirza Boschma, Désirée Y. van Haaften-Visser, Maaike C. de Vries, Roos Dijkstra, Amaya Zinck, Esmeralda Oussoren, Terry G. J. Derks, Andrea B. Haijer-Schreuder","doi":"10.1002/jmd2.70121","DOIUrl":"10.1002/jmd2.70121","url":null,"abstract":"<p>Inherited metabolic diseases (IMDs) are individually (ultra)rare but collectively relatively common. The Extension for Community Healthcare Outcomes (ECHO) model has been used worldwide since 2003 to disseminate knowledge and best practices in chronic diseases. In 2024, the Dutch Society for Inborn Errors of Metabolism (ESN) launched a pilot Metabolic Diseases ECHO Program. We aimed to evaluate whether ECHO is a feasible model for IMD knowledge dissemination. We conducted a retrospective review of the design, implementation, and impact of the program. Since February 2025, two ECHO hubs have been established in two Dutch medical education and training regions (ETRs). Data have been prospectively collected through the iECHO platform. Program impact was assessed using Moore's Expanded Outcomes Framework, covering seven levels ranging from participation and satisfaction to competence development and population outcomes. The Metabolic Diseases ECHO Program has achieved broad geographic reach and strong engagement among healthcare professionals. To date, 15 sessions have been completed and 10 additional sessions are scheduled. A total of 208 professionals from diverse disciplines, including pediatrics, clinical genetics, clinical chemistry, and nursing, have participated, representing 10 of the 12 Dutch provinces. The program has stimulated the development of two regional treatment protocols and integrates all core academic tasks: patient care, education, and research. The ECHO model is a feasible and sustainable approach for disseminating expertise on IMDs. Our program demonstrates meaningful impact across the first four levels of Moore's framework. Long-term continuation and expansion to other Dutch-speaking regions are under consideration. Future work will focus on assessing the direct benefits for IMD patients.</p>","PeriodicalId":14930,"journal":{"name":"JIMD reports","volume":"67 6","pages":""},"PeriodicalIF":1.8,"publicationDate":"2026-10-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13647106/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149136939","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}